1st Counsel – Lifestyle
Author:
Aligos Therapeutics
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
May 7, 2026
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2026
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
April 16, 2026
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
April 14, 2026
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
March 5, 2026